Atrial endothelial impairment through Toll-like receptor 4 signaling causes atrial thrombogenesis

Heart and Vessels

Volumn 29, Issue 2, 2014, Pages 263-272

  Katoh, Shigehiko ^a   Honda, Shintaro ^a   Watanabe, Tetsu ^a   Suzuki, Satoshi ^a   Ishino, Mitsunori ^a   Kitahara, Tatsuro ^a   Funayama, Akira ^a   Netsu, Shunsuke ^a   Sasaki, Toshiki ^a   Shishido, Tetsuro ^a   Miyamoto, Takuya ^a   Sadahiro, Mitsuaki ^a   Kubota, Isao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Atrial endothelium; Atrial fibrillation; Heart failure; Innate immunity; Thrombogenesis

Indexed keywords

CHAPERONIN 60; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PLASMINOGEN ACTIVATOR INHIBITOR 1; TOLL LIKE RECEPTOR 4; VASCULAR CELL ADHESION MOLECULE 1; HSPD1 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; NOS3 PROTEIN, MOUSE; TLR4 PROTEIN, HUMAN; TLR4 PROTEIN, MOUSE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME PHOSPHORYLATION; FEMALE; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART FAILURE; HEART VALVE REPLACEMENT; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; ATRIAL FIBRILLATION; BLOOD; C57BL MOUSE; CASE CONTROL STUDY; COMPLICATION; DEFICIENCY; DISEASE MODEL; ENDOTHELIUM CELL; GENETICS; HEMODYNAMICS; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; THROMBOSIS;

ANIMALS; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; CHAPERONIN 60; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HEART ATRIA; HEART FAILURE; HEMODYNAMICS; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIAL PROTEINS; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE III; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIGNAL TRANSDUCTION; THROMBOSIS; TOLL-LIKE RECEPTOR 4; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84897025397     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-013-0369-3     Document Type: Article

References (48)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946-952 (Pubitemid 28446646)
2. Acosta S, Ogren M, Bengtsson H, Bergqvist D, Lindblad B, Zdanowski Z (2006) Increasing incidence of ruptured abdominal aortic aneurysm: a population-based study. J Vasc Surg 44:237-243 (Pubitemid 44142935)
3. Maisel AS, Nakao K, Ponikowski P, Peacock WF, Yoshimura M, Suzuki T, Tsutamoto T, Filippatos GS, Saito Y, Seino Y, Minamino N, Hirata Y, Mukoyama M, Nishikimi T, Nagai R (2011) Japanese-Western consensus meeting on biomarkers. Int Heart J 52:253-265
4. Lindsay ME, Dietz HC (2011) Lessons on the pathogenesis of aneurysm from heritable conditions. Nature 473:308-316
5. Yamashita T, Sekiguchi A, Iwasaki YK, Sagara K, Hatano S, Iinuma H, Aizawa T, Fu LT (2003) Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation 108:2450-2452 (Pubitemid 37444404)
6. Goette A, Bukowska A, Lendeckel U, Erxleben M, Hammwohner M, Strugala D, Pfeiffenberger J, Rohl FW, Huth C, Ebert MP, Klein HU, Rocken C (2008) Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 117:732-742 (Pubitemid 351640674)
7. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137:263-272
8. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR (2001) C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104:2886-2891 (Pubitemid 33139098)
9. Conway DS, Buggins P, Hughes E, Lip GY (2004) Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 43:2075-2082 (Pubitemid 38686805)
10. Watanabe T, Takeishi Y, Hirono O, Itoh M, Matsui M, Nakamura K, Tamada Y, Kubota I (2005) C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels 20:45-49 (Pubitemid 40425252)
11. Savelieva I, Kakouros N, Kourliouros A, Camm AJ (2011) Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 13:308-328
12. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C (1999) Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100:376-380 (Pubitemid 29362407)
13. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107:2926-2931 (Pubitemid 36736634)
14. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ (2005) Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45:1832-1839 (Pubitemid 40789940)
15. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB (2005) Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45:712-719 (Pubitemid 40282586)
16. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA (1999) Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104:271-280
17. Eißler R, Schmaderer C, Rusai K, Kühne L, Sollinger D, Lahmer T, Witzke O, Lutz J, Heemann U, Baumann M (2011) Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res 34:551-558
18. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347:185-192 (Pubitemid 34764822)
19. Ohashi K, Burkart V, Flohe S, Kolb H (2000) Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol 164:558-561 (Pubitemid 30043672)
20. Schafler AE, Kirmanoglou K, Balbach J, Pecher P, Hannekum A, Schumacher B (2002) The expression of heat shock protein 60 in myocardium of patients with chronic atrial fibrillation. Basic Res Cardiol 97:258-261 (Pubitemid 34464160)
21. McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441-1446
22. Burke MA, Cotts WG (2007) Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev 12:23-36 (Pubitemid 46629244)
23. Sadanaga T, Kohsaka S, Mitamura H, Ogawa S (2011) Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation. Heart Vessels 26:530-535
24. Tamura H, Watanabe T, Nishiyama S, Sasaki S, Wanezaki M, Arimoto T, Takahashi H, Shishido T, Miyashita T, Miyamoto T, Hirono O, Kayama T, Kubota I (2012) Elevated plasma brain natriuretic peptide levels predict left atrial appendage dysfunction in patients with acute ischemic stroke. J Cardiol 60:126-132
25. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S (1999) Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 11:443-451 (Pubitemid 29504199)
26. Harada M, Takeishi Y, Arimoto T, Niizeki T, Kitahara T, Goto K, Walsh RA, Kubota I (2007) Diacylglycerol kinase zeta attenuates pressure overload-induced cardiac hypertrophy. Circ J 71:276-282 (Pubitemid 46182705)
27. Niizeki T, Takeishi Y, Kitahara T, Arimoto T, Ishino M, Bilim O, Suzuki S, Sasaki T, Nakajima O, Walsh RA, Goto K, Kubota I (2008) Diacylglycerol kinase-epsilon restores cardiac dysfunction under chronic pressure overload: a new specific regulator of Galpha(q) signaling cascade. Am J Physiol Heart Circ Physiol 295:H245-H255
28. Zhai P, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J, Irie K, Holle E, Yu X, Kupershmidt S, Roden DM, Wagner T, Yatani A, Vatner DE, Vatner SF, Sadoshima J (2005) Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 115:3045-3056 (Pubitemid 41567570)
29. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, Hoshii Y, Tanaka N, Ricci R, Ishihara T, Esato K, Hamano K, Matsuzaki M (2005) Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 11:1330-1338 (Pubitemid 41752914)
30. Saba S, Janczewski AM, Baker LC, Shusterman V, Gursoy EC, Feldman AM, Salama G, McTiernan CF, London B (2005) Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. Am J Physiol Heart Circ Physiol 289:H1456-H1467 (Pubitemid 41368987)
31. Schirger JA, Grantham JA, Kullo IJ, Jougasaki M, Wennberg PW, Chen HH, Lisy O, Miller V, Simari RD, Burnett JC Jr (2000) Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. J Am Coll Cardiol 35:796-801 (Pubitemid 30170255)
32. Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, Tarin C, Mas S, Ortiz A, Egido J (2011) Animal models of cardiovascular diseases. J Biomed Biotechnol 2011:497841
33. Matsumoto K, Ogawa M, Suzuki J, Hirata Y, Nagai R, Isobe M (2011) Regulatory T lymphocytes attenuate myocardial infarction-induced ventricular remodeling in mice. Int Heart J 52:382-387
34. Saito T, Watanabe M, Kojima T, Matsumura T, Fujita H, Kiyosue A, Takahashi M, Takeda N, Maemura K, Yamashita H, Hirata Y, Komatsu S, Ohtomo K, Nagai R (2011) Successful blood sampling through azygos continuation with interrupted inferior vena cava. A case report and review of the literature. Int Heart J 52:327-330
35. Annambhotla S, Bourgeois S, Wang X, Lin PH, Yao Q, Chen C (2008) Recent advances in molecular mechanisms of abdominal aortic aneurysm formation. World J Surg 32:976-986
36. Lin KM, Lin B, Lian IY, Mestril R, Scheffler IE, Dillmann WH (2001) Combined and individual mitochondrial HSP60 and HSP10 expression in cardiac myocytes protects mitochondrial function and prevents apoptotic cell deaths induced by simulated ischemia-reoxygenation. Circulation 103:1787-1792 (Pubitemid 32291417)
37. Gupta S, Knowlton AA (2002) Cytosolic heat shock protein 60, hypoxia, and apoptosis. Circulation 106:2727-2733 (Pubitemid 35364929)
38. Kol A, Bourcier T, Lichtman AH, Libby P (1999) Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 103:571-577 (Pubitemid 29094058)
39. Kol A, Sukhova GK, Lichtman AH, Libby P (1998) Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 98:300-307 (Pubitemid 28348051)
40. Daugherty A, Manning MW, Cassis LA (2000) Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105:1605-1612 (Pubitemid 30390311)
41. Law MR, Frost CD, Wald NJ (1991) By how much does dietary salt reduction lower blood pressure? I - analysis of observational data among populations. BMJ 302:811-815
42. Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J, Zhao A, Haddad GE, Williams DL, William Browder I, Kao RL, Li C (2005) Reduced cardiac hypertrophy in Toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 68:224-234 (Pubitemid 41428419)
43. Hollestelle SC, De Vries MR, Van Keulen JK, Schoneveld AH, Vink A, Strijder CF, Van Middelaar BJ, Pasterkamp G, Quax PH, De Kleijn DP (2004) Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 109:393-398 (Pubitemid 38139309)
44. Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, Thaler J, Hawn TR, Raines EW, Schwartz MW (2007) Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 100:1589-1596 (Pubitemid 46897262)
45. Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, Esmon CT (2011) Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 118:1952-1961
46. Traub O, Berk BC (1998) Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol 18:677-685 (Pubitemid 28267645)
47. Yang QW, Mou L, Lv FL, Wang JZ, Wang L, Zhou HJ, Gao D (2005) Role of Toll-like receptor 4/NF-kappaB pathway in monocyte-endothelial adhesion induced by low shear stress and ox-LDL. Biorheology 42:225-236 (Pubitemid 40719241)
48. Li YH, Lai LP, Shyu KG, Hwang JJ, Ma HM, Ko YL, Kuan P, Lien WP (1994) Clinical implications of left atrial appendage function: its influence on thrombus formation. Int J Cardiol 43:61-66 (Pubitemid 24061134)